Invitris
YC W23 · Active · Creating new protein-based drugs at scale
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Not stated | EF2021 | |
| AI | Active | YCS21 | |
| Other | Active | YCS21 | |
| AI | Inactive | YCW23 | |
| AI | Active | YCW17 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCW15 | |
| AI | Active | YCS19 | |
| Other | Public | YCS20 | |
| Other | Active | YCW23 | |
| AI | Active | YCW20 |
Also from W23
All of W23About Invitris
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
- YC batch
- W23 · Winter 2023
- Status, per YC
- Active
- Category
- Other
- Team size
- 6
- Location
- Munich, BY, Germany
- Checked
- 1h ago
YC tags: Biotech, Nanotechnology, Drug discovery
Invitris: questions
Which YC batch was Invitris in?
Invitris was in Y Combinator's Winter 2023 batch (W23).
Is Invitris still active?
Y Combinator lists Invitris as active.
Where is Invitris based?
Invitris lists Munich, BY, Germany as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.